On July 7, 2026, the U.S. Food and Drug Administration granted accelerated approval to Trutakna (atacicept‑vymj), a once‑weekly subcutaneous biologic developed by Vera Therapeutics, Inc., to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.3,5
Trutakna is the first FDA‑approved therapy that simultaneously targets B‑cell activating factor (BAFF) and A proliferation‑inducing ligand (APRIL), two upstream cytokines that promote survival and maturation of B cells involved in generating the pathogenic galactose‑deficient IgA1 (Gd‑IgA1) driving IgAN.3,15
Administered as a 150 mg self‑injection once weekly using a single‑dose autoinjector, Trutakna joins a rapidly growing IgAN treatment landscape that now includes budesonide (Tarpeyo), sparsentan (Filspari), iptacopan (Fabhalta), and sibeprenlimab (Voyxact), all launched since 2021 after decades in which supportive care was the only standard.13
Disease context: IgAN in 2026
IgA nephropathy, also known as Berger’s disease, is characterized by deposition of IgA‑containing immune complexes in the glomerular mesangium, triggering chronic inflammation, proteinuria, and progressive loss of kidney function.14,18
Recent U.S. claims‑based analyses estimate that approximately 198,000–208,000 people were living with IgAN in 2021, confirming it as one of the leading causes of primary glomerulonephritis and chronic kidney disease worldwide.1,14
Historically, care has focused on optimized supportive measures—blood‑pressure control, maximally tolerated ACE inhibitor or ARB therapy, and, more recently, SGLT2 inhibitors—guided by KDIGO, with only steroids and nonspecific immunosuppression available for high‑risk patients.12,19
Between 2021 and 2025, KDIGO guidelines evolved to incorporate mechanism‑specific treatments such as targeted‑release budesonide (Nefecon/Tarpeyo), the dual endothelin/angiotensin receptor antagonist sparsentan, and complement‑pathway inhibitors like iptacopan, reflecting a shift toward intervening both on pathogenic IgA production and intrarenal hemodynamic and inflammatory responses.9,10,13
Mechanism of action: dual BAFF/APRIL blockade
Atacicept‑vymj is a soluble, recombinant fusion glycoprotein based on the human TACI receptor, in which the ligand‑binding domain of TACI is fused to an engineered IgG1 Fc region and expressed in Chinese hamster ovary (CHO) cells.7,15
The molecule binds BAFF with high affinity (reported dissociation constant ~106 pM) and APRIL at ~33 pM, intercepting both cytokines before they can signal through their native receptors on B cells.7,15
Because BAFF and APRIL independently support B‑cell survival, maturation, and immunoglobulin production, dual blockade is designed to more completely suppress generation of pathogenic Gd‑IgA1 than targeting either cytokine alone, thereby reducing formation of nephritogenic immune complexes in the glomeruli.3,7
In the ORIGIN 3 program, Trutakna produced large, rapid pharmacodynamic effects: Vera has reported mean reductions by Week 36 of roughly 68% in Gd‑IgA1, alongside substantial declines in total IgA, IgM, and IgG, supporting the mechanistic link between dual BAFF/APRIL inhibition and proteinuria reduction.7
In plain‑language terms, BAFF and APRIL function like two independent fuel lines feeding the B‑cell “factory” that overproduces harmful IgA in IgAN; Trutakna is engineered to shut off both lines at once, rather than partially throttling a single fuel source.3
Vera originally in‑licensed atacicept from Merck KGaA and then repositioned it into IgAN, where its competitive edge lies in being the first dual BAFF/APRIL inhibitor approved in the U.S., ahead of Vertex’s povetacicept, which is following closely behind.7,10
Clinical evidence: ORIGIN 3 Phase 3
ORIGIN 3 (NCT04716231) is a global, multicenter, randomized, double‑blind, placebo‑controlled Phase 3 trial in adults with biopsy‑confirmed primary IgAN, persistent proteinuria despite optimized supportive care, and eGFR ≥30 mL/min/1.73 m².3,4,61
Patients were required to have UPCR ≥1 g/g (or ≥1.0 g/24 hours), remain on a maximal tolerated ACE inhibitor/ARB regimen with or without SGLT2 inhibitor and/or mineralocorticoid receptor antagonist, and have no recent exposure to systemic immunosuppressive therapy or other glomerular diseases.16
Participants were randomized 1:1 to receive Trutakna 150 mg or placebo, both as weekly subcutaneous injections, and the FDA’s accelerated approval was based on a prespecified interim analysis in the first 203 patients to reach the 9‑month (Week 36) visit.4,59
Primary endpoint (proteinuria)
At 9 months, Trutakna‑treated patients achieved an average 46% reduction from baseline in 24‑hour UPCR, compared with essentially no improvement in the placebo arm.3,4
The placebo‑adjusted treatment effect was reported as a 42% reduction, with tight confidence intervals and high statistical significance (p<0.0001), matching the figures summarized in Vera’s communications and third‑party coverage.3,4
Baseline characteristics showed a mean age of about 40 years, 57% male, with a majority of patients enrolled from Asian sites and only around 15% from the U.S.; mean eGFR was roughly 65 mL/min/1.73 m² and geometric mean UPCR about 1.5 g/g, representing a population with substantial but not end‑stage impairment.16
Subgroup analyses reported broadly consistent proteinuria reduction across age, sex, race, baseline eGFR strata, and presence or absence of SGLT2 inhibitor background therapy, suggesting that the effect is robust across typical IgAN subpopulations.7,15
Supportive data: ORIGIN Phase 2b and long‑term results
Earlier ORIGIN Phase 2b data over 96 weeks demonstrated sustained reductions in Gd‑IgA1, hematuria, and proteinuria with atacicept, alongside stabilization of kidney function, providing the biological plausibility and long‑term signal that ORIGIN 3 expands into a registrational dataset.7
Key limitations of the evidence
Proteinuria is a surrogate endpoint: FDA explicitly notes that it has not yet been established whether Trutakna slows long‑term kidney‑function decline, and continued approval is contingent on verification of eGFR benefit in the ongoing blinded 2‑year ORIGIN 3 study.4
Exposure duration in the interim analysis is modest—median ~34 weeks in the Trutakna arm vs ~31 weeks on placebo—leaving safety and durability beyond 9 months to be defined by the full trial.16
Geographic distribution (majority non‑U.S. sites, very low enrollment of Black patients) may limit direct generalizability to the full U.S. IgAN population, an important consideration for payers and guideline committees.2,18
Safety profile and “clean label”
Trutakna’s label carries no boxed warning and no Risk Evaluation and Mitigation Strategy (REMS) requirement; regulators instead emphasize two core themes: infection risk and vaccine management.3
Infections
In the 428‑patient ORIGIN 3 safety population, infections of any kind occurred in 32% of Trutakna‑treated patients versus 28% on placebo, with upper respiratory tract infection the most frequently reported single event (12% vs 9%).16
FDA and company materials state that Trutakna suppresses immune responses and may increase risk of infection, recommending that patients be assessed for active infections prior to initiation and monitored for signs and symptoms throughout treatment, with treatment interruption considered for serious infections.3
Local administration reactions
Local administration reactions, including injection‑site reaction and injection‑site erythema, occurred in 30% of Trutakna patients compared with 5% in the placebo arm (injection‑site reaction 19% vs 2%; erythema 6% vs 1%).16
These events were predominantly mild to moderate and generally resolved without requiring treatment interruption or discontinuation according to available data, although formal grade 3–4 breakdowns and precise discontinuation rates are not publicly detailed.7,15
Vaccination and immunogenicity
Because Trutakna may blunt immune responses to vaccines and increase risk from live attenuated vaccines, administration of live vaccines is not recommended within 30 days before starting therapy or at any time during treatment.3
Patients should complete age‑appropriate immunizations before initiation, and clinicians are advised to review vaccination status and defer live vaccines or adjust schedules accordingly.3
Anti‑drug antibodies were detected in a substantial minority of treated patients in pooled Phase 2/3 data (around 40–45% through Week 36), but no clinically meaningful impact on pharmacokinetics, pharmacodynamics, safety, or efficacy was observed over that period.7
Contraindications, special populations, and interactions
Contraindication is limited to serious hypersensitivity to atacicept‑vymj or any excipients.11
Use in pregnancy and lactation carries standard biologic immunosuppression cautions: human data are insufficient, in‑utero exposure may lead to transient immunosuppression in the infant, and animal studies showed malformations only at maternally toxic high‑multiple exposures.7,11
Safety and efficacy have not been established in pediatric populations, and geriatric data are limited but do not suggest major pharmacokinetic differences; the label notes no formal dose adjustments for renal or hepatic impairment based on studied ranges.11
No dedicated CYP450 or QTc interaction studies are required for this biologic; however, concurrent use with other immunomodulators, including systemic corticosteroids or cytotoxic agents, has not been systematically studied and may theoretically increase infection risk.11
Overall, the safety picture is consistent with a targeted immunomodulatory biologic: manageable injection‑site and infection signals, a need for careful vaccine planning and infection monitoring, and a reassuring lack of boxed warnings or REMS obligations at launch.3
Dosing and administration in practice
Trutakna is supplied as a 150 mg/mL solution in a 1 mL single‑dose pre‑filled autoinjector with a 27‑gauge needle and needle guard, designed for self‑administration after appropriate training.11
The recommended dose is 150 mg subcutaneously once weekly, with no loading dose; if a dose is missed, patients should administer it as soon as possible and then resume the weekly schedule one week after that catch‑up injection.11
Administration technique and storage
Patients or caregivers inject into the abdomen (except for a 2‑inch radius around the navel) or thigh, rotating sites with each dose; injections into the upper arm may be possible if a caregiver performs them.11
The autoinjector should be stored refrigerated and protected from light, allowed to sit at room temperature for 15–30 minutes before injection, and must not be frozen, shaken, or exposed to external heat sources; one 72‑hour room‑temperature window is allowed, after which the device should not be returned to the refrigerator.15
For prescribers, key implementation tasks include confirming optimized supportive care (maximal RAS blockade, blood‑pressure control, lifestyle measures), screening for active infection, reviewing vaccination status, and planning monitoring (proteinuria, eGFR, infection signs) over time.6,12
Pharmacists and nurses play critical roles in patient education on storage, injection technique, recognition of infection or hypersensitivity symptoms, and coordination with Vera’s TRU SUPPORT program for access and copay support.7,15
Patient burden, access, and pricing
Trutakna’s once‑weekly, at‑home autoinjector format reduces the logistical burden compared with infusion‑center therapies, though it requires more frequent injections than Voyxact’s once‑every‑four‑weeks regimen.11,17
From an access standpoint, Vera has set a wholesale acquisition cost of $32,700 per four‑dose (28‑day) carton, translating to roughly $425,000 per year—slightly higher than reported list pricing around $390,000 annually for Voyxact.8
To mitigate out‑of‑pocket impact, Vera is launching Trutakna with the TRU SUPPORT program, under which eligible commercially insured patients may pay as little as $0, alongside hub services for benefits verification and patient onboarding.7,15
Real‑world uptake is likely to depend on payer assessments of comparative effectiveness, long‑term kidney‑function data (once eGFR results become available), and positioning relative to lower‑priced or oral options, especially in health systems.9,10,34
FAQs About Trutakna FDA Approval:
How does Trutakna’s dual BAFF/APRIL mechanism differ from other IgAN therapies?
Trutakna (atacicept‑vymj) is the first FDA‑approved therapy that simultaneously inhibits BAFF and APRIL, two B‑cell survival cytokines that drive production of galactose‑deficient IgA1 in IgA nephropathy.1
Most existing IgAN drugs act downstream (e.g., endothelin/angiotensin blockade with sparsentan, corticosteroid targeting of mucosal immunity with budesonide, complement factor B inhibition with iptacopan) or block APRIL alone (Voyxact), whereas Trutakna intervenes upstream at B‑cell biology, aiming to suppress the abnormal IgA production itself.
What clinical evidence supports Trutakna’s approval, and what data are still missing?
FDA’s accelerated approval is based on the prespecified Week 36 interim analysis from the Phase 3 ORIGIN 3 trial, where atacicept achieved a 46% reduction from baseline in UPCR and a placebo‑adjusted proteinuria reduction of 42% (p<0.0001) in adults with biopsy‑proven IgAN.1
However, the approval rests on proteinuria as a surrogate endpoint; long‑term kidney‑function data (eGFR slope over 2 years) are still pending and will determine whether Trutakna’s accelerated approval can be converted to full approval and how it compares with Fabhalta’s 49.3% two‑year eGFR preservation signal.4
What are the key safety concerns with Trutakna, and how should clinicians mitigate them?
The main safety concerns are infection risk and injection‑site reactions: infections occurred in roughly one‑third of treated patients vs slightly fewer on placebo, with upper respiratory tract infections most common, and local injection reactions (including erythema) were substantially more frequent than with placebo in ORIGIN 3.1,16
Clinicians should screen for active infections before initiation, update age‑appropriate vaccinations (avoiding live vaccines within 30 days before and during treatment), monitor closely for infection symptoms, and counsel patients on proper autoinjector use and site rotation to minimize local reactions.1,11,15
Where does Trutakna fit in current KDIGO IgAN treatment algorithms?
KDIGO’s updated IgAN guidance recommends optimized supportive care (RAS blockade, strict blood‑pressure control, SGLT2 inhibitors where appropriate) as the foundation, then adds targeted agents for patients with persistent proteinuria ≥1 g/day and high risk of progression.
In this framework, Trutakna is best positioned as a biologic add‑on for adults with biopsy‑confirmed primary IgAN, sustained proteinuria despite guideline‑directed supportive therapy, and preserved eGFR (≥30 mL/min/1.73 m²), similar to the ORIGIN 3 population, while long‑term eGFR data will determine whether it moves closer to first‑line status among biologics.
Does Trutakna have orphan drug status, and what does that mean for patients?
In the European Union, atacicept holds EMA orphan designation for primary IgA nephropathy (EU/3/24/2985), which provides regulatory incentives like fee reductions and market exclusivity if approved, but does not itself authorize patient use.
In the United States, FDA’s public materials for Trutakna emphasize accelerated approval, priority review, and Breakthrough Therapy designation, but do not list orphan drug status, so patients and payers should not assume U.S. orphan incentives or protections based on the EMA designation alone.1
References:
- Xiong C, et al. The incidence and prevalence of immunoglobulin A nephropathy in the United States. Kidney Int. 2025;xx(x):xxx–xxx.
- Wyatt RJ, Julian BA. IgA nephropathy (Berger disease). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
- U.S. Food and Drug Administration. FDA approves new treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy. Silver Spring (MD): FDA; 2026 Jul 6.
- EMPR. Trutakna approved to reduce proteinuria in primary IgA nephropathy. EMPR; 2026 Jul 7.
- U.S. Food and Drug Administration. Novel drug approvals 2026. Silver Spring (MD): FDA; 2026.
- KDIGO. Key takeaways for clinicians – IgA nephropathy. Kidney Disease: Improving Global Outcomes; 2021.
- Vera Therapeutics, Inc. Kidney disease‑focused Vera Therapeutics concludes enrollment in pivotal study, targets 2026 commercial launch. Finance Yahoo; 2025 Apr 3.
- American Journal of Managed Care. FDA approves sibeprenlimab for immunoglobulin A nephropathy. AJMC; 2025 Nov 30.
- Novartis. IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%. Novartis Media Release; 2026 Mar 28.
- GxP News. The US Food and Drug Administration approves the first dual‑target drug for IgA nephropathy. GxP News; 2026 Jul 8.
- Medscape. Trutakna (atacicept) dosing, indications, interactions, adverse effects. Medscape Reference; 2026.
- KDIGO. Glomerular Diseases (GD) guideline. Kidney Disease: Improving Global Outcomes; 2021–2025.
- Guideline Central. Treatment of IgAN – KDIGO guidelines timeline (2021–2025). Guideline Central; 2025 Oct 5.
- Li X, et al. IgA nephropathy: epidemiology, outcomes, and insights for primary care. Kidney Int Rep. 2026;xx(x):xxx–xxx.
- Pharmaceutical Commerce. What Trutakna’s approval means for specialty launches. Pharm Commerce; 2026 Jul 6.
- Investing.com. Vera Therapeutics erhält FDA‑Zulassung für Nierenmedikament Trutakna. Investing.com (DE); 2026 Jul 6.
- NephCure. VOYXACT (sibeprenlimab) – treatment options for IgA nephropathy. NephCure; 2025 Dec 10.
- Schena FP, et al. IgA nephropathy: epidemiology and outcomes. Kidney Int. 2024;xx(x):xxx–xxx.
- KDIGO. Glomerular disease guideline update 2025. Kidney Disease: Improving Global Outcomes; 2025.
